Metrosa (Metronidazole)

Metronidazole penetrates microbial cells and, under anaerobic conditions, is reduced to reactive nitro radicals. These radicals bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, which leads to death of anaerobic bacteria and protozoa responsible for the targeted skin condition.

The dosage of Metrosa is determined by the prescribing clinician based on the specific indication, severity of the condition, and patient factors. The prescriber will provide detailed instructions on the amount to apply, frequency, and duration of therapy.

Safety of topical metronidazole during pregnancy or lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Metrosa.

To order Metrosa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metrosa (topical metronidazole) is a well‑established option for mild to moderate papulopustular rosacea, offering anti‑inflammatory and antimicrobial effects. Alternative agents include azelaic acid, ivermectin cream, and doxycycline (oral). Choice of therapy depends on disease severity, patient tolerance, and physician preference.

Metrosa should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and extreme heat. Ensure the lid is tightly closed to maintain product stability.

Metrosa is applied topically to the affected skin area. Clean and gently pat the skin dry, then spread a thin layer of the product as directed by the prescriber, usually once or twice daily. Avoid contact with eyes, mucous membranes, and broken skin unless instructed otherwise.

Serious risks, though rare with topical use, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and toxic epidermal necrolysis. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, swelling, or difficulty breathing.

Metrosa should not be used by individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. It is also contraindicated on severely damaged or ulcerated skin unless specifically advised by a healthcare professional.